Teva Continues Divestitures To Close Allergan Deal With Sale To Impax
Executive Summary
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.
Topics
- Subjects
- Companies
- Deals
- Business Strategies
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC065478
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC065478
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.